← All trials
NCT04841720
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2021
- Primary completion
- Jun 30, 2021
- Completion date
- Aug 15, 2021
- First posted
- Apr 12, 2021
- Last posted
- Apr 12, 2021
- Enrollment
- 22
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Haisco PharmaceuticalLead sponsor
- Hebei UniversityCollaborator
- Hebei Medical UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.